Skin cancer is one of the most prevalent and potentially life-threatening cancers globally, making it a critical area of focus in medical research. Early detection, followed by timely and appropriate treatment, can significantly enhance patient survival outcomes. In recent years, computer-aided diagnostic systems have gained substantial attention for their ability to support accurate and efficient skin cancer diagnosis. This study presents an optimized stacked ensemble strategy to improve skin lesion classification performance. Experiments were conducted on the Melanoma Skin Cancer Dataset using four different convolutional neural network (CNN) architectures, each trained with different optimizers, including Adam, Stochastic Gradient Descent (SGD), Root Mean Square Propagation (RMSprop), and AdaMax (Adamax). All models were trained using categorical cross-entropy loss and evaluated based on validation accuracy, with hyperparameters such as learning rate, batch size, and number of epochs kept constant. More than 90 model combinations were tested using four ensemble strategies: soft and hard voting, weighted voting (using grid search), and stacked ensemble using various meta-learners (Gradient Boosting (GB), k-Nearest Neighbors (KNN), Support Vector Machine (SVM), Logistic Regression (LR), and Naïve Bayes (NB)). The models and ensembles were assessed using standard performance metrics including accuracy, precision, recall, F1-score, and Area Under the Receiver Operating Characteristic Curve (ROC-AUC). Among the evaluated configurations, the stacked ensemble model with Gradient Boosting (GB) as the meta-classifier and M1+M2+M3+M4 as the deep learning base models achieved a validation accuracy of 97.4% and a robust independent test accuracy of 91.80% with a ROC-AUC of 96.87%. The findings demonstrate that ensemble learning, particularly stacked ensembling, significantly enhances classification accuracy and strengthens the reliability of melanoma detection on unseen datasets.
Trending
- FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach
- 95 monarchE: Subgroup Analysis of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer by Nodal Status
- 96 Efficacy and Safety of Abemaciclib in Younger Patients With Early Breast Cancer in the monarchE Trial
- GPX8+ cancer-associated fibroblast-derived lactate contributes to lenvatinib resistance by facilitating BRPF1 expression through histone H3 lysine 18 lactylation in hepatocellular carcinoma
- Crochet group donates beanies to cancer patients
- Scientists warn popular vitamin D supplement may have a “previously unknown” downside
- An oncostatin M receptor and chloride intracellular channel 1 crosstalk drives key oncogenic pathways in glioblastoma
- Quizartinib Regimen Appears Effective in FLT3-ITD+ AML Trial

